[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"norm-eurlex-reg_2016_1198-erwgr-4-de":3},{"law":4,"norm_id":14,"norm_key":15,"slug":16,"title":17,"chapter":18,"content":19,"enriched_content":20,"hierarchy":21,"neighbors_before":22,"neighbors_after":32,"citing_decisions":42,"is_thin":43},{"abbreviation":5,"title":6,"source_type":7,"jurisdiction":8,"document_kind":9,"language":10,"attribution":11,"version_date":12,"source_url":13},"reg_2016_1198","zur Änderung von Anhang V der Verordnung (EG) Nr. 1223\u002F2009 des Europäischen Parlaments und des Rates über kosmetische Mittel","eurlex","eu","regulation","de","© Europäische Union, https:\u002F\u002Feur-lex.europa.eu","2025-02-06","https:\u002F\u002Feur-lex.europa.eu\u002Flegal-content\u002FDE\u002FALL\u002F?uri=CELEX:32016R1198",7050739,"ErwGr. 4","erwgr-4",null,"Erwägungsgründe","Angesichts der Stellungnahme des SCCS muss auf den Anstieg von Allergien durch Methylisothiazolinon eingegangen werden; dieser Stoff sollte daher in Leave-on-Produkten verboten werden.","REG_2016_1198 - Erwägungsgründe - ErwGr. 4\n\nAngesichts der Stellungnahme des SCCS muss auf den Anstieg von Allergien durch Methylisothiazolinon eingegangen werden; dieser Stoff sollte daher in Leave-on-Produkten verboten werden.",{},[23,26,29],{"norm_key":24,"title":17,"slug":25},"ErwGr. 3","erwgr-3",{"norm_key":27,"title":17,"slug":28},"ErwGr. 2","erwgr-2",{"norm_key":30,"title":17,"slug":31},"ErwGr. 1","erwgr-1",[33,36,39],{"norm_key":34,"title":17,"slug":35},"ErwGr. 5","erwgr-5",{"norm_key":37,"title":17,"slug":38},"ErwGr. 6","erwgr-6",{"norm_key":40,"title":17,"slug":41},"ErwGr. 7","erwgr-7",[],false]